Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A guide to COVID‐19 antiviral therapeutics: a summary and perspective of the antiviral weapons against SARS‐CoV‐2 infection
Drugan K. Brady, Aashi R. Gurijala, Liyu Huang, et al.
FEBS Journal (2022) Vol. 291, Iss. 8, pp. 1632-1662
Open Access | Times Cited: 19

Showing 19 citing articles:

COVID‐19 in early 2023: Structure, replication mechanism, variants of SARS‐CoV‐2, diagnostic tests, and vaccine & drug development studies
İlker Polatoğlu, Tülay Öncü Öner, Irem Dalman, et al.
MedComm (2023) Vol. 4, Iss. 2
Open Access | Times Cited: 43
Evaluation of antiviral drugs against newly emerged SARS-CoV-2 Omicron subvariants
Jun‐Hyung Cho, Younmin Shin, Jeong‐Sun Yang, et al.
Antiviral Research (2023) Vol. 214, pp. 105609-105609
Open Access | Times Cited: 20
Synergism between remdesivir and ribavirin leads to SARS‐CoV‐2 extinction in cell culture
Carlos García‐Crespo, Ana Isabel de Ávila, Isabel Gallego, et al.
British Journal of Pharmacology (2024) Vol. 181, Iss. 15, pp. 2636-2654
Open Access | Times Cited: 6
A year in the molecular life sciences: 2024 highlights
Julija Hmeljak, Hajrah Khawaja, Séamus J. Martin
FEBS Journal (2025)
Closed Access
COVID-19: Lessons Learned from Molecular and Clinical Research
Manuela Rizzi, Pier Paolo Sainaghi
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 2, pp. 616-616
Open Access
Recommendations for the diagnosis and treatment of anti-neutrophil cytoplasmic autoantibody associated vasculitis
Enrique Morales, Íñigo Rúa‐Figueroa, José Luis Callejas‐Rubio, et al.
Nefrología (English Edition) (2025)
Open Access
Interferons in COVID-19: missed opportunities to prove efficacy in clinical phase III trials?
Josef Brzoska, Harald von Eick, Manfred Hündgen
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 9
Phenothiazines Inhibit SARS-CoV-2 Entry through Targeting Spike Protein
Taizhen Liang, Shiqi Xiao, Ziyao Wu, et al.
Viruses (2023) Vol. 15, Iss. 8, pp. 1666-1666
Open Access | Times Cited: 6
Structural insights into the RNA binding inhibitors of the C-terminal domain of the SARS-CoV-2 nucleocapsid
Preeti Dhaka, Jai Krishna Mahto, Ankur Singh, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Chemically modified antiviral peptides against SARS‐CoV‐2
Michael Quagliata, Anna Maria Papini, Paolo Rovero
Journal of Peptide Science (2023)
Open Access | Times Cited: 2
Factors Influencing Non-Adherence to Antiretroviral Therapy Among HIV/AIDS Patients in Western Sumatra: Implications for Practice in the Post-COVID-19 Era
Adriani Suwito, Ikhwana Elfitri, Afriwardi, et al.
International Journal of Design & Nature and Ecodynamics (2024) Vol. 19, Iss. 1, pp. 311-320
Open Access
Anti-SARS-CoV-2 glyco-humanized polyclonal antibody XAV-19: phase II/III randomized placebo-controlled trial shows acceleration to recovery for mild to moderate patients with COVID-19
Garyphallia Poulakou, Pierre‐Joseph Royer, Nikolay Evgeniev, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Inhibition of SARS-CoV-2 Replication by Self-Assembled siRNA Nanoparticles Targeting Multiple Highly Conserved Viral Sequences
Jianan Sun, Siya Lu, Jizhen Xiao, et al.
Viruses (2024) Vol. 16, Iss. 7, pp. 1072-1072
Open Access
Recomendaciones para el diagnóstico y tratamiento de las vasculitis asociadas a anticuerpos anticitoplasma de neutrófilo
Enrique Morales, Íñigo Rúa‐Figueroa, José Luis Callejas‐Rubio, et al.
Nefrología (2024)
Open Access
Bebtelovimab‐bound SARS‐CoV‐2 RBD mutants: resistance profiling and validation with escape mutations, clinical results, and viral genome sequences
Khushboo Bhagat, Shweata Maurya, Amar Jeet Yadav, et al.
FEBS Letters (2024)
Closed Access
Lactoferrin Supplementation in Preventing and Protecting from SARS-CoV-2 Infection: Is There Any Role in General and Special Populations? An Updated Review of Literature
Paolo Manzoni, Alessandro Messina, Chiara Germano, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 19, pp. 10248-10248
Open Access
SSCBDTA: Prediction of Drug-Target Binding Affinity with Secondary Sequences and Multiple Cross-Attention Blocks
Haiwei Zuo, Pengcheng Zhou, Xia Li, et al.
Research Square (Research Square) (2024)
Open Access
Evaluation of antiviral drugs against newly emerged SARS-CoV-2 Omicron subvariants
Jun‐Hyung Cho, Younmin Shin, Jeong‐Sun Yang, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
XAV-19 a Glyco-Humanized polyclonal antibody targeting SARS-CoV-2 accelerates the recovery of mild to moderate COVID-19 patients and keeps its neutralizing activity against Omicron and its subvariants
Garyphallia Poulakou, Pierre‐Joseph Royer, Nikolai Evgeniev, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
Page 1

Scroll to top